A Randomized , Double -Blinded, Placebo-Controlled Phase 3 Study to assess the Efficacy and safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older.
The development of a vaccine for Coronavirus disease -19 (COVID-19) will be critical for containing the current outbreak and preventing future outbreaks, as no vaccine is currently available.
Janssen is developing a vaccine for the prevention of SARS-CoV-2-mediated COVID-19 in adults.
In this study efficacy, safety and Immunogenicity will be evaluated in adults living in or going to locations with high risk of SARS-CoV-2 infection after vaccine administration.
To demonstrate the efficacy of AD26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to Placebo, in SARS-CoV-2 Seronegative adults.
Adults 18 Years and Older
Janssen Pharmaceutical Companies of Johnson Johnson
Latest Update: 15 February 2021
For more about Jansen ENSEMBLE VAC31518COV3001 HG please email firstname.lastname@example.org